Olympus Corp. (JP:7733)
:7733
Want to see JP:7733 full AI Analyst Report?
7733 Stock Chart & Stats
¥1583.50
¥60.50(2.58%)
At close: 4:00 PM EST
¥1583.50
¥60.50(2.58%)
Day’s Range― - ―
52-Week Range¥1,302.50 - ¥2,168.00
Previous CloseN/A
Volume4.23M
Average Volume (3M)3.67M
Market Cap
¥1.89T
Enterprise Value¥2.12T
Total Cash (Recent Filing)¥188.04B
Total Debt (Recent Filing)¥239.58B
Price to Earnings (P/E)24.3
Beta0.81
Next Earnings
Aug 12, 2026EPS Estimate
9.75Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)61.37
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)2.04
Price to Sales (P/S)1.64
P/FCF Ratio36.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,125.00Price Target Upside34.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)87.61
Revenue Forecast (FY)¥1.05T
Bulls Say, Bears Say
Bulls Say
Stable Revenue Growth & High Gross MarginsConsistent multi-year top-line growth combined with persistently high gross margins supports durable earnings power and pricing leverage. This underpins recurring consumables/service revenue tied to installed base and reduces vulnerability to cyclical capital spending swings over the medium term.
Strengthening Balance Sheet And Lower LeverageMarked reduction in leverage and expanding equity provide structural financial flexibility to fund remediation, R&D, and capex without excessive refinancing risk. A stronger balance sheet supports sustained investment in product lifecycle and service networks, improving resilience over 2–6 months.
Clear Remediation Plan And Management CommitmentManagement has articulated a detailed QA/regulatory remediation plan, global harmonization of quality systems, and has released a majority of held products. These structural actions, plus leadership appointments and stated margin targets, materially reduce regulatory overhang and support phased recovery.
Bears Say
Volatile Cash Generation And Weak FCF ConversionLarge swings in operating cash and free cash flow reduce predictability of internally generated funds for capex, R&D and working capital. Volatile cash conversion increases reliance on balance sheet buffers and heightens execution risk during remediation and restructuring over the coming quarters.
Ongoing FDA Observations And Product Ship-holdsOpen FDA observations and remaining product holds constrain revenue recovery and sustain incremental remediation and compliance costs. Regulatory uncertainty limits market access and sales cadence for affected portfolios until inspections are closed, impeding growth in the medium term.
Near-term Profitability Pressure From One-off Costs And RestructuringElevated one-off COGS (disposals, recalls) plus accelerated JPY 31bn restructuring provisioning depress margins and create timing distortions in reported profitability. Execution risk around achieving the stated JPY 24bn savings leaves medium-term margin recovery contingent on successful cost realization.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1302.50 and its highest was ¥2168.00 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.89T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Aug 12, 2026 which is in 84 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on May 12, 2026. The company reported ¥22.45 earnings per share for the quarter, beating the consensus estimate of ¥7.648 by ¥14.802.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Undervalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.01%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate is 9.75.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥22.45 in its last earnings report, beating expectations of ¥7.648. Following the earnings report the stock price went down -0.677%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
7733 Company Deck
7733 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.View all JP:7733 earnings summaries7733 Stock 12 Month Forecast
Average Price Target
¥2,125.00
▲(34.20% Upside)
Technical Analysis
Options Prices
Currently, No data available
---